Last reviewed · How we verify

NCT06806696

SARS-COV-2 VARIANTS' EFFECT ON PREGNANCY AND LONG-TERM OUTCOMES AMONG PREGNANT WOMEN AND THEIR NEWBORNS IN ESTONIA

Completed Last updated 4 February 2025
What this trial tests

trial testing COVID-19 infection in Pregnancy in 60,739 participants. Completed in 1 March 2023.

Timeline
27 February 2020
Primary endpoint
1 March 2023
1 March 2023

Quick facts

Lead sponsorUniversity of Tartu
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60,739
Start date27 February 2020
Primary completion1 March 2023
Estimated completion1 March 2023
Sites1 location across Estonia

Drugs / interventions tested

Conditions studied

Sponsor

University of Tartu

Who can join

Eligibility, any sex, with Pregnancy or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of the study is to describe the possible impacts of SARS-CoV-2 and its various genotypes on pregnancy and long-term outcomes among pregnant women and their newborns in Estonia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of COVID-19 infection

Trials testing the same drug.

Other recruiting trials for Pregnancy

Currently open trials in the same condition.

Other University of Tartu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06806696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing